Antimicrobial de-escalation (ADE) is a strategy to reduce the spectrum of antimicrobials and aims to prevent the emergence of bacterial resistance. We present a systematic review describing the definitions, determinants and outcomes associated with ADE. We included 2 randomized controlled trials and 12 cohort studies. There was considerable variability in the definition of ADE. It was more frequently performed in patients with broad-spectrum and/or appropriate antimicrobial therapy (P = .05 to .002), when more agents were used (P = .002), and in the absence of multidrug-resistant pathogens (P < .05). Where investigated, lower or improving severity scores were consistently associated with ADE (P = .04 to <.001). The pooled effect of ADE on mortality is protective (relative risk, 0.68; 95% confidence interval, .52-.88). Because the determinants of ADE are markers of clinical improvement and/or of lower risk of treatment failure this effect on mortality cannot be retained as evidence. None of the studies were designed to investigate the effect of ADE on antimicrobial resistance.
Antimicrobial de-escalation (ADE) of antimicrobial therapy is a strategy proposed to allow for the rational use of broadspectrum antimicrobial therapy as the empiric treatment for infections and minimize the overall exposure to these broadspectrum agents. The need for prompt, effective antimicrobial therapy for patients with known or suspected infections is widely accepted. This principle leads to the use of very broadspectrum antimicrobial therapy to increase the odds that all suspected potential pathogens are adequately treated. However, the potential drawback is selection of multidrug-resistant (MDR) organisms.
ADE is widely recommended in the management of antimicrobial therapy in intensive care unit (ICU) patients [1] [2] [3] . The Surviving Sepsis Campaign guidelines [2] describe and recommend the process for selecting antimicrobial therapy as (1) commencement of antimicrobials within the first hour, (2a) antimicrobial therapy broad enough to cover all likely pathogens, and (2b) daily reassessment for potential ADE.
A recent Cochrane review found "no adequate, direct evidence as to whether ADE of antimicrobial agents is effective and safe for adults with sepsis, severe sepsis or septic shock" [4] . With this background, we performed a systematic search for evidence supporting ADE in ICUs. Our aims were to review and analyze (1) the definitions used for ADE, (2) the determinants and factors associated with ADE, (3) the effects of ADE on outcomes, and (4) the impact of the strategy on antimicrobial usage, bacterial resistance and costs.
METHODS
Methods of the analysis and inclusion criteria were specified in advance and registered through PROSPERO (CRD42013006944; registered 23 December 2013).
Search Strategy
A search of MEDLINE , EMBASE (all years), and the Cochrane library was conducted to identify suitable publications using the following search terms: (antibiotics OR antimicrobials OR antibacterials) AND (de-escalation OR deescalate OR narrowing OR step-down OR stepdown OR streamline) AND (ICU OR intensive care OR critical care OR septic shock OR severe sepsis OR sepsis). The searches were limited to studies fully published in the English language. The resulting outputs were combined, excluding duplicate results. Abstracts were scanned for suitability and the full text retrieved for all potentially relevant studies. Bibliographies and reference lists were reviewed to identify additional relevant studies. Conference, congress, and scientific meeting abstracts were not included. A MEDLINE alert was created to remain informed of any new studies being published with the same search string and was stopped on 1 September 2015.
Study Content Inclusion Criteria
The following inclusion criteria were used to assess the retrieved studies: (1) ADE of antimicrobial therapy, (2) an intensive care setting, and (3) application of any intervention or provision of substantial epidemiological data to judge the effects or determinants of ADE. Studies that did not include antibacterial agents were not included. Studies that reported ADE of antimicrobials as part of the results but did not provide specific information on the reasons, modalities or effects of such ADE were also excluded from the review.
Quality Inclusion Criteria
Each study was independently evaluated by 2 reviewers (A. T. and M. O. C.) using quality inclusion specifications derived from the Cochrane Effective Practice and Organization of Care (EPOC) Review Group [5] . We included uncontrolled before-and-after, case-control, and cohort studies if they met the criteria of measurement and reporting of potential confounding variables between periods or patient groups. Any disagreement between the 2 reviewers was resolved after asking the opinion of 2 other reviewers (J. S. and J. R. Z.). The quality of included studies was appraised using the Cochrane Risk of Bias tool for randomized controlled trials (RCTs) [6] , and a modified version ( provided in the Supplement) of the Newcastle-Ottawa Scale for case-control and cohort studies [7] . The scale was modified to match the specifics of this review after 3 rounds of discussions to reach agreement between 5 investigators (A. T., M. O. C., J. G. M., J. S., and J. R. Z.). It included 3 domains with 7 questions, for a maximum of 8 points.
Data Analysis and Statistical Methods
Three reviewers (A. T., J. G. M., and J. S.) independently appraised each included study. Interrater agreement was calculated with free marginal κ statistics [8] . The relative risk (RR) ratio with 95% confidence intervals (CIs) was calculated to assess the association between ADE and mortality rates. Heterogeneity among studies was evaluated using the χ 2 test based on the Cochran Q statistic and quantified by the I 2 value [9] . Because the level of heterogeneity indicated a moderate level of diversity in the results of the studies, pooled RRs were calculated using both the fixed-effects model and the random-effects model proposed by DerSimonian and Laird [10] , with the Egger test used for publication bias. Relevant factors associated with performing ADE versus non-ADE at the level of significance of 5% were extracted from each publication. Factors influencing rates of ADE versus escalation were excluded. Data and P values are reported as from original publications. All analyses were conducted using Stata 12.1 software (StataCorp).
RESULTS

Search Results, Grading, and Study Quality
The results of our search strategy are detailed in Figure 1 . The 14 included studies are summarized in Table 1 . Two open-label randomized trials were included. One compared initial broadspectrum antimicrobials (a carbapenem and a glycopeptide) with a strategy excluding these. Appropriateness of initial empiric antibiotic therapy differed between the groups (75.9% vs 48.0%; P = .04) [18] . Because this trial compared the effectiveness of 2 different empiric antimicrobial therapy strategies, and not the safety or effectiveness of ADE, it was excluded from further analysis. The other study randomized ADE and a continuation strategy in 120 patients treated with antibiotics for severe sepsis in 9 ICUs [23] . Aside from the open-label design, the main risks of bias were a low inclusion rate and an imbalance in baseline characteristics between the 2 groups, including the initial use of broad-spectrum antibiotics, age, severity scores, and site of infections.
Grading showed "almost perfect" interrater agreement among the 3 reviewers (κ = 1), both studies being nonblinded, with complete outcome, no selective reporting, and the other risks of bias as described above. The grading for the 12 cohort studies is detailed in Table 1 ; mean grades ranged from 4 to 7, with "substantial" interrater agreement among reviewers (κ = 0.61; 95% CI, .51-.71). One study was multicentric [11] , 4 were prospective [11, 12, 21, 22] . Five investigated ADE exclusively in patients with a respiratory tract infection [11-13, 16, 20] . Three included patients with severe sepsis or septic shock [17, 21, 22] . Two studies reported ADE in an unselected population [15, 19] , 2 included exclusively patients with cancer or neutropenia [21, 24] , and 1 included only cases with empiric carbapenem therapy [14] . The reported ADE rate ranged from 34% to 62%.
Definitions
There was no uniform definition of ADE (Table 2 ). In some studies ADE was evaluated only in case of "very" broad empiric therapy, whereas in others ADE was assessed irrespective of initial antimicrobial therapy. ADE was always described as narrowing or "streamlining" the spectrum of antimicrobials, with a ranking of agents' spectra of activity provided in 4 of the 13 studies [12, 16, 20, 23] . Ten studies provided either a specific day or range of 2-5 days after initiation of broad-spectrum empiric therapy for which ADE had to occur [11-17, 19, 20, 23, 24] . ADE included decreasing the number of antimicrobials in 13 studies [11-13, 15-17, 19-24] . Four studies included shortening the duration of antimicrobial therapy in the definition of ADE [15, 16, 19, 24] .
Leone and colleagues [23] used the concept of a "pivotal" antimicrobial, usually an extended-spectrum β-lactam, together with an agent used to treat methicillin-resistant Staphylococcus aureus (MRSA) and a "companion" antimicrobial (aminoglycoside or fluoroquinolone or macrolide). ADE was defined as switching from the pivotal antibiotic to a narrower agent, stopping the companion antibiotic at day 3 of therapy, and ceasing anti-MRSA therapy when not required. None of the studies described the ADE (vs non-ADE) status as rated by blinded investigators.
Factors Associated With ADE
Microbiological documentation [14, 17, 21] , such as a positive blood culture [22] or the use of invasive sampling in ventilator-associated pneumonia [12] , and initially appropriate antimicrobial therapy were consistently correlated with ADE (P = .05 to .002) [13, 15, 17, 19, 21, 22] (summary in Table 3 , full report in the Supplement). Likewise, an initial empiric broad-spectrum treatment [19, 21] , compliance with guidelines to start antipseudomonal β-lactams in neutropenic patients (P = .01) [21] , or the use of several agents and companion drugs were all correlated with ADE (P = .002) [15] .
A lower baseline severity [11, 24] or clinical resolution at the time of culture results (when ADE can be considered) increased the rate of ADE. Garnacho-Montero et al [22] reported lower Sepsis-related Organ Failure Assessment (SOFA) scores at the moment of ADE (P = .04), Knaak et al [20] and Paskovaty et al [24] both reported a higher delta SOFA score (surrogate for improvement in organ failures) (P < .001 and .002, respectively), and Joung et al [16] reported lower modified Clinical Pulmonary Infection Score (CPIS) and Acute Physiology and Chronic Health Evaluation (APACHE) II scores at day 5 (P = .03 and .002), all occurring more frequently in the ADE group. Likewise, recovery from neutropenia was associated with ADE (P = .05) in a cohort of neutropenic sepsis [21] .
Conversely, infection with an MDR pathogen significantly reduced the likelihood of ADE in 4 studies (P < .05) [11, 14, 15, 19] . Polymicrobial infections (P < .05) [20, 22] , multiple concomitant infections (P = .02) [24] , and infections with a high risk of undiagnosed pathogens, such as intra-abdominal infections, were associated with non-ADE (P = .02) [14, 22] or escalation (P < .01) [22] . Outcomes After ADE Based on the primary end point of ICU length of stay and a noninferiority margin of 2 days, the recent RCT did not demonstrate noninferiority of the ADE strategy [23] . There was a higher rate of superinfections requiring antimicrobial therapy in the ADE group (27% vs 11%; P = .03), of which 44% were due to the initial pathogen.
Two cohort studies looked at a follow-up of 7-14 days [11, 16] . The others followed up the patients for the duration of either ICU or hospital admission or for ≥28 days. Data comparing mortality rates between ADE and non-ADE groups, involving a total of 1688 patients, are reported in Figure 2 . The pooled estimate of mortality showed a protective effect of ADE (RR, 0.68; 95 CI, .52-.88) with moderate heterogeneity (I 2 = 44.2%). We did not Outcomes varied from similar response [11] and mortality [13-15, 19, 21, 24] rates to a decrease in length of stay [12, 24] and mortality rates [12, 16, 17, 20, 22] . None of the studies reported a worse survival with the ADE strategy. All publications lacked a precise description as to how the outcome was assessed. Furthermore, confounders such as an incompletely described cohort [12] , an imbalance in patient characteristics at baseline [15, 23] , or "at the moment of ADE" [16, 20] introduced high risk of bias.
Adjustment and multivariable analysis on the effect of ADE on outcome were provided in 5 publications [11, 16, 21, 22, 24] . In a cohort of neutropenic sepsis, ADE had no influence on 30-day (hazard ratio [HR], 0.51; 95% CI, .20-1.33) or 1-year mortality rates [21] . Two studies accounted for severity at the moment where ADE was considered. After adjustment with a propensity score, Garnacho-Montero et al [22] showed that ADE was protective (odds ratio [OR], 0.55; P = .022). Higher SOFA scores on the day of culture results (OR, 1.11; P < .001), septic shock (OR, 1.70; P = .043), and inadequate empiric antimicrobial therapy (OR, 2.03; P = .03) were all independently associated with mortality. In a cohort of patients with ICUacquired pneumonia, after adjustment with a Cox model, severity scores (APACHE II and CPIS) at day 5 were the only independent predictors of pneumonia-related and all-cause mortality [16] .
Effect of ADE on the Duration of Antimicrobial Therapy
To avoid misinterpreting the effect of ADE on the duration of antimicrobial therapy, we excluded studies that allowed for shortening or discontinuation of therapy as part of the definition of ADE in this part of the analysis [15, 16, 19, 24] . Four studies compared the duration of antimicrobial therapy between ADE and non-ADE groups [11, [21] [22] [23] . There was no reduction in antibiotic days with ADE. One study reported an increase in the duration of therapy with ADE (9 vs 5 days; P = .005) [21] .
Effect of ADE on Microbiological Flora and Antimicrobial Resistance
None of the studies were designed to investigate the effect of ADE (or non-ADE) on the acquisition of MDR bacteria. Gonzalez and colleagues did not show any difference in the carriage or ICU-acquired infections with MDR bacteria between the 2 groups [19] . Leone et al [23] reported that no effect on local ecology at day 8 was found.
Cost Analysis
Two studies reported lower costs in patients with ADE [11, 20] . This was explained not by a higher market price for broadspectrum antimicrobial therapy but by an overall decrease in expenses due to the same factors that tend to increase the rate of ADE, such as lower severity or clinical improvement [20] . In turn, this led to shorter ICU and hospital stays for patients in the ADE group, further contributing to lower costs associated with this cohort [11] .
DISCUSSION
In this systematic review we found a paucity of studies looking at the effect of a ADE strategy on duration of antimicrobial therapy, emergence of resistance or costs. We found an association between ADE and better patient outcomes. We describe a high risk of bias in the cohort studies. Most importantly, because this effect was not confirmed in the only available RCT, these data should not be read as a causal association between ADE and outcomes.
ADE was variably defined across the studies, making comparability problematic. There are inherent difficulties in defining ADE. Weiss and a group of French-speaking experts [25] used a Delphi method to propose a definition of ADE. They provided a 6-rank classification of β-lactams according to their spectrum and resistance promoting potential. Reaching a consensus for the ranking of ureidopenicillins and carboxypenicillins, third-and fourth-generation antipseudomonal cephalosporins required 4 Delphi rounds, highlighting the difficulty in ranking drugs even within a single class of antimicrobials. Madaras-Kelly and colleagues [26] developed a spectrum score and calculated piperacillin-tazobactam at a higher value and broader spectrum than those for imipenem or meropenem, opposite to the findings from Weiss et al [25] . Leone et al [23] have provided a pragmatic definition of ADE with the concept of pivotal antibiotic, on which ADE efforts focus, together with cessation of companion antibiotics if they are not required.
We found that ADE was associated with reduced mortality. However, the clinical and statistical heterogeneity in our meta-analysis questions the validity of this result. We found heterogeneity in study design and populations, in the definition of ADE, and in the adjustment for confounding variables. Where investigated, improving severity scores are associated with an increased rate of ADE [16, 20, 22, 24] . In the cohort with the largest weight, the authors attempted to minimize bias by performing a propensity score adjusted multivariable analysis. Although it is a state-of-the-art statistical adjustment, it is not possible to exclude an interaction with clinical improvement, because it is a determinant for both mortality rate and performance of ADE [22] . In patients with improving severity scores, it is not known how many were already microbiologically and/or clinically cured. For those patients, ADE may not have influenced outcome. As such, outside of a randomized setting, ADE could be considered a marker of clinical improvement, whereas the reluctance to narrow the antimicrobial spectrum may indicate deterioration.
The ADE strategy is advocated to limit the emergence of resistance to antimicrobial therapy. Although resistance emergence has been studied for shortening treatment [27] , to date there is no evidence of this for ADE because none of the published studies was designed to evaluate this variable. Broad-spectrum antimicrobials have been associated with resistance among gastrointestinal tract flora [28] . Although, intuitively, it seems that giving a narrower-spectrum antibiotic might reduce the emergence of resistance, this remains to be investigated. The increased number of superinfections with ADE in a randomized trial [23] , of which 44% were due to the initial pathogen, might be related to the higher risk of nonachievement of pharmacokinetic/pharmacodynamic targets with narrow-spectrum compared with broad-spectrum antimicrobials found in simulation studies [29] . ADE has been investigated as the simple component of care to decrease antimicrobial spectrum based on culture results. However, it is dependent on multiple other factors, such as risk, severity and improvement, site of infection, adequacy of source control, and factors that will vary with each treatment, microorganism, patient, and institution. As such, ADE should be regarded as a process part of the global antimicrobial stewardship approach, inclusive of other elements such as the route and mode of administration and the total duration of antimicrobial therapy.
The main limitation of this work resides in its initial concept to provide more information than the available meta-analysis and to allow for the inclusion of cohort studies. Inferring an effect on outcomes from such studies is associated with a high risk of accepting bias. In addition, limiting the inclusion to studies published in English may have introduced further bias. Furthermore, because we did not include studies that limited their analysis to only antifungal or antiviral drugs, our findings are not applicable to those classes of antimicrobials.
In conclusion, there is no uniform definition of ADE. It is more commonly performed in patients with improving severity scores and those receiving broad-spectrum antimicrobials. ADE did not reduce the total duration of antimicrobial treatment costs or length of stay. The effects of ADE on bacterial resistance have not been adequately investigated. Although the pooled estimate shows a protective effect of ADE on mortality, there is too much bias to retain this result as evidence for a direct beneficial effect. This leads us to conclude that equipoise remains and a large cluster-randomized trial is required to assess the effect of the ADE strategy on the bacterial ecosystem, on MDR carriage, and on patient outcomes.
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